Not Yet RecruitingNCT07615075
Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia
Medication studyAges 18–64United States
Understand this study
Who could participate?
Listed age limits: 18 years to 64 years.
- Listed locations
- CatonsvilleSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: September 1, 2026
- Recruitment status
- Not Yet Recruiting
- Enrollment listed in the registry
- 40
- Sponsor
- University of Maryland, Baltimore
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT07615075
- Official title
Show the full official title
Randomized Double-Blind Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia
Recruitment & locations
Not yet recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Catonsville
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Maryland, Baltimore, a university.
Does this study involve medication?
Yes. The study involves medication, including Placebo and IL-23.
Who can participate?
Listed age limits: 18 years to 64 years.
Is this study still recruiting?
The registry lists this study as not yet recruiting.
